echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical trial application of recombinant human parathyroid hormone for injection, a wholly-owned subsidiary of Buchang Pharmaceuticals, has been accepted

    The clinical trial application of recombinant human parathyroid hormone for injection, a wholly-owned subsidiary of Buchang Pharmaceuticals, has been accepted

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 1, Buchang Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Luzhou Buchang’s "recombinant human parathyroid hormone (1-84) for injection" clinical trial application was recently accepted by the National Medical Products Administration.


    Luzhou Buchang obtained the clinical trial of recombinant human parathyroid hormone (1-84) for injection this time.


    The proposed indications of recombinant human parathyroid hormone (1-84) for injection include: 1.


    Hypoparathyroidism is a group of clinical syndromes caused by undersecretion of parathyroid hormone (PTH) and/or insufficient effect


    At present, the globally marketed similar drug is Takeda's Natpara®, which was approved for marketing by the US FDA in 2015


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.